Financial

  • Jul. 29, 2021 Bioasis Announces Filing of Its First Quarter Financial Statements and MD&A

    NEW HAVEN, Conn., July 29, 2021 (GLOBE NEWSWIRE) — Bioasis Technologies Inc. (TSX.V:BTI; OTCQB:BIOAF) (the “Company” or “Bioasis”),a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3TM platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including… Read more »

  • Jun. 29, 2021 Bioasis Technologies Announces Closing of Initial C$3,000,000 Funding by Lind Partners

    NEW HAVEN, Conn., June 29, 2021 (GLOBE NEWSWIRE) — Bioasis Technologies Inc. (“Bioasis” or the “Company”) (TSX.V:BTI; OTCQB:BIOAF), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 TM platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders in areas of high unmet medical need, including brain… Read more »

  • Jun. 25, 2021 Bioasis Announces Filing of Its Fourth Quarter and Fiscal Year-End Financial Statements and MD&A

    NEW HAVEN, Conn., June 25, 2021 (GLOBE NEWSWIRE) — Bioasis Technologies, Inc. (TSXV:BTI.V; OTCQB:BIOAF), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 ™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need,… Read more »

  • Jun. 22, 2021 Bioasis Technologies enters into Convertible Security Funding Agreement for Institutional Investment of up to C$10 million

    NEW HAVEN, Conn., June 22, 2021 (GLOBE NEWSWIRE) — Bioasis Technologies Inc. (“Bioasis” or the “Company”) (TSX.V:BTI; OTCQB:BIOAF), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 TM platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders in areas of high unmet medical need, including brain… Read more »

  • Jan. 27, 2021 Bioasis Announces Filing of Its Quarter and Financial Statements and MD&A for the Period Ending November 30, 2020

    GUILFORD, Conn., Jan. 27, 2021 (GLOBE NEWSWIRE) — Bioasis Technologies Inc.?(TSX.V:BTI; OTCQB:BIOAF) (the “Company” or “Bioasis”),?a?pre-clinical, research-stage?biopharmaceutical company developing its proprietary?xB3 TM?platform?technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases,?today announced… Read more »

  • Oct. 29, 2020 Bioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending August 31, 2020

    GUILFORD, Conn., Oct. 29, 2020 (GLOBE NEWSWIRE) — Bioasis Technologies, Inc. (TSXV:BTI.V; OTCQB:BIOAF), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 ™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need,… Read more »

  • Oct. 22, 2020 Bioasis Announces Analyst Coverage Initiated by Zacks Investment Research

    GUILFORD, Conn., Oct. 22, 2020 (GLOBE NEWSWIRE) — Bioasis Technologies, Inc. (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 ™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need,… Read more »

  • Jul. 27, 2020 Bioasis Announces Filing of Its Quarter and Financial Statements and MD&A for the Period Ending May 31, 2020

    GUILFORD, Conn.–(Business Wire)– Bioasis Technologies, Inc. (TSXV:BTI.V; OTCQB:BIOAF), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced it has… Read more »

  • Jul. 7, 2020 Bioasis Announces Stock Option Grants

    GUILFORD, Conn.–(Business Wire)– Bioasis Technologies, Inc. (TSXV:BTI.V; OTCQB:BIOAF), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced that it… Read more »

  • Jun. 29, 2020 Bioasis Announces Filing of Its Fourth Quarter and Fiscal Year-End Financial Statements and MD&A

    GUILFORD, Conn.–(Business Wire)– Bioasis Technologies, Inc. (TSXV:BTI.V; OTCQB:BIOAF), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases,… Read more »